NavaClick IRB Study
2024 | PN 3047, Rev B
Study Design
The study employed a prospective observational design 4 investigative sites. Participants aged 18 or older, already scheduled for neurotoxin injections, were eligible to be enrolled. Additionally, participants must have received at least one previous neurotoxin injection to qualify for inclusion in the study. After providing informed consent, participants received injections using the NavaClick™ Injection System. Following each treatment, investigators and participants completed questionnaires assessing their experience.
Touch-Up Data
Site 1 reports a significant reduction in touch-ups following the use of the NavaClick™ Injection System. A 'touch-up' is defined as “a patient returning with undesired clinical results from a neurotoxin procedure — within four weeks of injection — despite having received appropriate clinical dosing.” Of the 122 participants enrolled at Site 1, only one participant required a touch-up (a touch-up rate of 0.82%) compared with Site 1's 2023 touch up rate of 4.5%.
Overall Satisfaction
100% of investigators like the click and trust the precision
7 of 8 investigators agree they provide a higher standard of care
3 of 4 participants are likely to request it for future injections and recommend it to a friend
Reduced Complications
LESS BRUISING & PAIN
91% of participants reported NO bruising or LESS bruising with NavaClick
84% of participants experienced less pain with NavaClick
Simple. Accurate. Efficient.
The IRB Study confirms that the NavaClick Injection System simplifies the preparation and delivery of neurotoxins, provides greater site and dosing accuracy, improves overall efficiency, and reduces neurotoxin waste.
Click here to download copy of the IRB Study Results.
